Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.

All transretinoic acid (ATRA) gives complete remission (CR) rates of 80 to 90% in newly diagnosed acute promyelocytic leukemia (APL). However, it has two major drawbacks (1) a rapid rise in WBC in some patients, with potentially fatal ATRA syndrome (2) rapid relapse with maintenance therapy using ATRA alone or low dose chemotherapy. The French APL group therefore designed a treatment approach with ATRA followed by intensive chemotherapy. The latter was administered after CR achievement with ATRA, or was rapidly added to ATRA in case of rapid rise in leukocyte counts. This combined approach, in a pilot study and in a randomized trial, proved superior to intensive chemotherapy alone, by slightly increasing the CR rate but more importantly by reducing the relapse rate. These results were confirmed by the Chinese, Japanese and New York groups. Our group (and other European groups) are now testing in a new randomized trial the better timing of ATRA and chemotherapy administration (ATRA followed by chemotherapy or ATRA plus chemotherapy) and the role (after an intensive consolidation) of maintenance treatment with intermittent ATRA, continuous low dose chemotherapy or both.

[1]  E. Dmitrovsky,et al.  All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study , 1994, Annals of Internal Medicine.

[2]  N. Komatsu,et al.  Acute promyelocytic leukaemia, tretinoin, and granulocyte colony-stimulating factor , 1994, The Lancet.

[3]  H. Tilly,et al.  Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia , 1993 .

[4]  R. Krance,et al.  Tretinoin toxicity in children with acute promyelocytic leukaemia , 1993, The Lancet.

[5]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[6]  T. Naoe,et al.  Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia , 1993 .

[7]  M. Villalona-Calero,et al.  Acute progranulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF) , 1993, Leukemia.

[8]  P. Fenaux,et al.  Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. , 1993, Blood.

[9]  W. Strober,et al.  Functional abnormalities of CD8+ T cells define a unique subset of patients with common variable immunodeficiency. , 1993, Blood.

[10]  P. Adamson,et al.  Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. , 1993, Cancer research.

[11]  T. Barbui,et al.  Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia , 1992, The Lancet.

[12]  H. Dombret,et al.  All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. , 1992, Blood.

[13]  R. Warrell,et al.  The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.

[14]  T. Naoe,et al.  Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. , 1992, Leukemia.

[15]  P. Marlton,et al.  Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis , 1992 .

[16]  M. Tallman,et al.  Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. , 1992, Blood.

[17]  E. Dmitrovsky,et al.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. , 1992, Blood.

[18]  H. Dombret,et al.  All trans retinoic acid treatment for patients with acute promyelocytic leukemia. , 1992, Leukemia.

[19]  Zi X. Chen,et al.  A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. , 1991, Blood.

[20]  G. Leverger,et al.  A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[22]  H. Dombret,et al.  Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid , 1990, The Lancet.

[23]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[24]  P. Fenaux,et al.  All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.

[25]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[26]  H. Kantarjian,et al.  Role of maintenance chemotherapy in acute promyelocytic leukemia , 1987, Cancer.

[27]  H. Koeffler,et al.  Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. , 1982, Experimental cell research.